NERV

Minerva Neurosciences' stock has been impacted by several events, including an expected $80 million funding through a private placement, reaching a market capitalization of US$271 million, and an analyst price target increase of 61% to US$7.25. A significant negative event was the FDA's "refusal to file" letter for roluperidone. The company also received a Nasdaq notice regarding non-compliance with minimum market value requirements. The stock has experienced high volatility and substantial dilution, but has also shown significant growth over the past year.